with the exception of teriparatide, which is reserved for women and men with the most severe osteoporosis, all of these newer drugs are first-line therapy for osteoporosis in postmenopausal women. However, only bisphosphonates are also currently approved for this indication in men and in patients ...
WNT7B, that stimulates new bone growth (shown in pink on the right). The protein could become a target for new drugs to treat osteoporosis and other conditions related to bone loss. Credit: Washington University
New evidence indicates that this protection also extends to osteoporosis (Table 2). This was first demonstrated with the first generation SIRT1 agonist, resveratrol: mice treated with resveratrol for 18+ months showed modest improvements (15%) in both trabecular and cortical bone mass, indicating ...
A new model, described today ineLife, may help improve outcomes for patients with postmenopausal osteoporosis and reduce the risks of side effects by helping physicians build more personalized treatment regimes. The sudden loss of the hormone estrogen during menopause can interfere with the body's na...
The gut microbiota (GM) plays a crucial role in maintaining the overall health and well-being of the host. Recent studies have demonstrated that the GM may significantly influence bone metabolism and degenerative skeletal diseases, such as osteoporosis (OP). Interventions targeting GM modification, ...
The gut microbiota (GM) plays a crucial role in maintaining the overall health and well-being of the host. Recent studies have demonstrated that the GM may significantly influence bone metabolism and degenerative skeletal diseases, such as osteoporosis (OP). Interventions targeting GM modification, ...
This is to say the least, big news for everyone who’s long been waiting for a drug that would speed the path to market of drugs that treat multiple age related illnesses. When this happens, aging will no longer be so dreary. We can all then look forward to longer, healthier lives. ...
Drugs 81:1831–1858. https://doi.org/10.1007/s40265-021-01625-8 Article CAS PubMed PubMed Central Google Scholar Migliorini F, Maffulli N, Spiezia F et al (2021) Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res 16:318. https://doi...
Ankylosing spondylitis (AS) is a common rheumatic disorder distinguished by chronic inflammation and heterotopic ossification at local entheses sites. Currently available medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs) and TNF inhibitors,...
for tissue repair and drug delivery. For example, some PHAs have been developed into injectable stem cell carriers [18], 3D in vitro cell culture carriers [19] bone TE scaffolds, nano-carriers for anti-osteoporosis therapy in microgravity [20], as well as for directional bone induction [21]...